Form 4: Centessa Pharmaceuticals Executive Exercises Options and Sells Shares

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, exercised options and sold 10,000 shares of company stock on November 25, 2024.

Summary

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, exercised options to acquire 10,000 ordinary shares at a price of $3.85 per share on November 25, 2024.
• On the same day, Weinhoff sold 10,000 ordinary shares at a weighted average price of $17.6601 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2024.
• Following these transactions, Weinhoff directly owns 183,266 ordinary shares.
• The share options were granted with a vesting schedule, with 1/48th of the shares vesting monthly starting March 1, 2023.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive, with no indication of positive or negative sentiment. It's a neutral event.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the share price.

Industry Context

This is a routine filing related to executive stock transactions, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their stock transactions.
• The vesting schedule of the options is typical for executive compensation packages.
• The price range of the share sales ($17.38 to $18.16) is within the expected market fluctuations for a company like Centessa Pharmaceuticals.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership by an executive.

Key Dates

Keywords

Centessa Pharmaceuticals, Gregory M. Weinhoff, stock options, share sale, Rule 10b5-1, insider trading, executive compensation